ArticleDiscover oncology2025
The impact of SRRM2-AS1 in ovarian cancer: a comprehensive analysis based on pan-cancer and in vitro validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLong non-coding RNAs (lncRNAs) have been extensively studied and are recognized for their crucial roles in cancer development. Among them, lncRNA SRRM2-AS1 has emerged as a significant factor, yet its functions in ovarian cancer remain insufficiently understood. MATERIALS AND
methodsWe analyzed SRRM2-AS1 expression and genetic alterations using data from TCGA, GEO, and cBioPortal. Enrichment analyses of differentially expressed genes (DEGs) associated with SRRM2-AS1 were conducted via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Immune cell infiltrations were assessed with the single-sample Gene Set Enrichment Analysis (ssGSEA) algorithm, while subcellular localization was predicted using the lncATLAS database. We conducted qRT-PCR and fluorescence in situ hybridization (FISH) to examine the expression and localization of SRRM2-AS1. Cellular assays were performed to assess the impact of SRRM2-AS1 inhibition in ovarian cancer.
resultsSRRM2-AS1 expression was significantly elevated in ovarian cancer tissues compared to normal tissues, as evidenced by data from TCGA, GTEx, and supported by the GSE18520 and GSE40595 datasets, along with our own samples (14 ovarian cancer tissues and 9 normal tissues). Receiver operating characteristic (ROC) analysis indicated its potential as a diagnostic biomarker with an Area Under the Curve (AUC) of 0.758. We identified 957 DEGs associated with SRRM2-AS1, with GO and KEGG enrichment analyses highlighting their involvement in microtubule-based movement, cilium movement and immune cell interactions. Immune infiltration analyses indicated significant correlations between SRRM2-AS1 expression and various immune cell types, suggesting its role in modulating the tumor microenvironment. Subcellular localization studies using the lncATLAS database, qRT-PCR, and FISH confirmed the nuclear predominance of SRRM2-AS1 in ovarian cancer cells. Functionally, SRRM2-AS1 knockdown inhibited ovarian cancer cell proliferation, migration, and invasion.
conclusionThese findings underscore the potential of SRRM2-AS1 as both a biomarker and a therapeutic target in ovarian cancer, highlighting the need for further investigation into its mechanistic roles and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.